Matches in SemOpenAlex for { <https://semopenalex.org/work/W2422177205> ?p ?o ?g. }
Showing items 1 to 93 of
93
with 100 items per page.
- W2422177205 endingPage "1371" @default.
- W2422177205 startingPage "1367" @default.
- W2422177205 abstract "An early phase II clinical study was done to investigate the activity and the safety of oral administration of etoposide for 21 consecutive days in patients with non-small-cell lung cancer. An interim analysis was done after registration of 24 cases. One case was a dropout because of an insufficient administration period (4 days). The other 23 cases were complete: they comprised 9 cases of adenocarcinoma, 13 cases of squamous cell carcinoma, and 1 case of large cell carcinoma. Prior therapy had not been given in two cases. The doses used were 50 mg/person/day in 12 cases and 75 mg/person/day in 11 cases. The response observed was one case of at 50 mg/person/day to stage IV squamous cell carcinoma, 17 cases were no change, 5 cases were progressing disease, and giving a response rate of 4.3% in complete cases. Considering those results, we decided that it would be difficult to achieve a 20% response rate by the end of this study, and therefore the study was terminated. The side effects of the regimen were tolerable. In conclusion, etoposide was not active against non-small-cell lung cancer at the dosage and schedule employed. Further investigation is required to obtain a more effective form of therapy." @default.
- W2422177205 created "2016-06-24" @default.
- W2422177205 creator A5003807078 @default.
- W2422177205 creator A5023160652 @default.
- W2422177205 creator A5036436409 @default.
- W2422177205 creator A5040926160 @default.
- W2422177205 creator A5055064044 @default.
- W2422177205 creator A5063155490 @default.
- W2422177205 creator A5065536577 @default.
- W2422177205 creator A5082778336 @default.
- W2422177205 creator A5083455636 @default.
- W2422177205 creator A5084195784 @default.
- W2422177205 date "1995-12-01" @default.
- W2422177205 modified "2023-10-18" @default.
- W2422177205 title "[Early phase II study of oral administration of etoposide for 21 consecutive days in patients with non-small-cell lung cancer]." @default.
- W2422177205 cites W142928982 @default.
- W2422177205 cites W1448754582 @default.
- W2422177205 cites W2038796952 @default.
- W2422177205 cites W2058142120 @default.
- W2422177205 cites W2155007470 @default.
- W2422177205 cites W2223919226 @default.
- W2422177205 cites W2236604469 @default.
- W2422177205 cites W2276477497 @default.
- W2422177205 cites W2415272997 @default.
- W2422177205 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8821989" @default.
- W2422177205 hasPublicationYear "1995" @default.
- W2422177205 type Work @default.
- W2422177205 sameAs 2422177205 @default.
- W2422177205 citedByCount "1" @default.
- W2422177205 crossrefType "journal-article" @default.
- W2422177205 hasAuthorship W2422177205A5003807078 @default.
- W2422177205 hasAuthorship W2422177205A5023160652 @default.
- W2422177205 hasAuthorship W2422177205A5036436409 @default.
- W2422177205 hasAuthorship W2422177205A5040926160 @default.
- W2422177205 hasAuthorship W2422177205A5055064044 @default.
- W2422177205 hasAuthorship W2422177205A5063155490 @default.
- W2422177205 hasAuthorship W2422177205A5065536577 @default.
- W2422177205 hasAuthorship W2422177205A5082778336 @default.
- W2422177205 hasAuthorship W2422177205A5083455636 @default.
- W2422177205 hasAuthorship W2422177205A5084195784 @default.
- W2422177205 hasConcept C121608353 @default.
- W2422177205 hasConcept C126322002 @default.
- W2422177205 hasConcept C141071460 @default.
- W2422177205 hasConcept C143998085 @default.
- W2422177205 hasConcept C146357865 @default.
- W2422177205 hasConcept C151730666 @default.
- W2422177205 hasConcept C2776256026 @default.
- W2422177205 hasConcept C2776694085 @default.
- W2422177205 hasConcept C2778119113 @default.
- W2422177205 hasConcept C2779292878 @default.
- W2422177205 hasConcept C2781182431 @default.
- W2422177205 hasConcept C2781413609 @default.
- W2422177205 hasConcept C3019992690 @default.
- W2422177205 hasConcept C31760486 @default.
- W2422177205 hasConcept C71924100 @default.
- W2422177205 hasConcept C86803240 @default.
- W2422177205 hasConceptScore W2422177205C121608353 @default.
- W2422177205 hasConceptScore W2422177205C126322002 @default.
- W2422177205 hasConceptScore W2422177205C141071460 @default.
- W2422177205 hasConceptScore W2422177205C143998085 @default.
- W2422177205 hasConceptScore W2422177205C146357865 @default.
- W2422177205 hasConceptScore W2422177205C151730666 @default.
- W2422177205 hasConceptScore W2422177205C2776256026 @default.
- W2422177205 hasConceptScore W2422177205C2776694085 @default.
- W2422177205 hasConceptScore W2422177205C2778119113 @default.
- W2422177205 hasConceptScore W2422177205C2779292878 @default.
- W2422177205 hasConceptScore W2422177205C2781182431 @default.
- W2422177205 hasConceptScore W2422177205C2781413609 @default.
- W2422177205 hasConceptScore W2422177205C3019992690 @default.
- W2422177205 hasConceptScore W2422177205C31760486 @default.
- W2422177205 hasConceptScore W2422177205C71924100 @default.
- W2422177205 hasConceptScore W2422177205C86803240 @default.
- W2422177205 hasIssue "12" @default.
- W2422177205 hasLocation W24221772051 @default.
- W2422177205 hasOpenAccess W2422177205 @default.
- W2422177205 hasPrimaryLocation W24221772051 @default.
- W2422177205 hasRelatedWork W1994507509 @default.
- W2422177205 hasRelatedWork W2181971546 @default.
- W2422177205 hasRelatedWork W2197997348 @default.
- W2422177205 hasRelatedWork W2316817489 @default.
- W2422177205 hasRelatedWork W2367084509 @default.
- W2422177205 hasRelatedWork W2377088845 @default.
- W2422177205 hasRelatedWork W2378830451 @default.
- W2422177205 hasRelatedWork W2396161326 @default.
- W2422177205 hasRelatedWork W2624751764 @default.
- W2422177205 hasRelatedWork W4242233721 @default.
- W2422177205 hasVolume "33" @default.
- W2422177205 isParatext "false" @default.
- W2422177205 isRetracted "false" @default.
- W2422177205 magId "2422177205" @default.
- W2422177205 workType "article" @default.